A federal judge rejected Novartis' request for a preliminary injunction to stop MSN Pharmaceuticals from selling a generic ...

A federal judge in New Jersey denied a preliminary injunction sought by Novartis (NYSE:NVS) to block MSN Pharmaceuticals from launching a generic version of the former’s blockbuster heart failure ...

Novartis Pharmaceuticals Corp. convinced the Federal Circuit to temporarily block MSN Pharmaceuticals Inc. from launching a ...

Novartis could soon face generic competition for Entresto after judge's ruling.

Novartis cannot block drugmaker MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug ...

Novartis stock fell early Thursday after the drugmaker reported light sales of Cosentyx, one of its biggest moneymakers.

Swiss pharmaceutical giant Novartis has raised its full-year earnings forecast, citing robust revenue growth from key ...

The pharmaceutical company raised its full-year profit guidance as ongoing demand for key drugs fueled growth in ...

Novartis said Thursday that it expects its Kisqali breast cancer treatment to be the next blockbuster drug within its portfolio. The Swiss pharma firm is looking to shift reliance away from its ...

CNBC's Karen Gilchrist weighs in on Novartis' second-quarter earnings and efforts to diversify its drug portfolio beyond its ...

"We did not expect Novartis to raise its FY guidance ahead of the generic entry to U.S. Entresto which continues to be expected per mid-year," wrote a Vontobel analyst. Novartis suffered a legal ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...